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treatment failure. Adjuvant chemotherapy improves survival, but the 
absolute gain is modest and generally limited to stage II-IIIA. High-risk 
pts may be identiﬁed by gene expression proﬁles and considered for 
adjuvant chemotherapy. 
Methods: Of a consecutive series of 174 pts who underwent curative 
pulmonary resection between 2000 and 2004, we selected 66 stage I-
IIIA SqCLC pts (64 pts stage I and II and 2 pts stage IIIA): 33 pts who 
developed distant metastases and 33 who were free of distant relapse 
after a median follow-up of 37 months (range, 24-64 months). Snap 
frozen primary tumor specimens were obtained at the time of surgery. 
Sections were taken from blocks of tumor tissue for RNA extraction, 
and gene expression of 29 genes was assessed by RT-PCR using low 
density arrays. Expression values were dichotomized using the median 
as a cut-off value. 
Results: The univariate analysis identiﬁed 10 genes with signiﬁcant 
prognostic value: CSF1, EGFR, CA IX, PH4, KIAA0974, ANLN, 
VEGFC, NTRK1, FN1, INR1. In the multivariate Cox model, CSF1 
[HR=3.5, p=0.005], EGFR [HR=2.7, p=0.02], CA IX [HR=0.2, 
p<0.0001] and tumor size >4 cm [HR=2,7, p=0.02] emerged as 
signiﬁcant predictors of survival. A risk score based on the expres-
sion of CSF1, EGFR and CA IX was 70% accurate in predicting death 
risk. This model also performed well in predicting development of 
distant metastases, with 64% sensitivity and 73% speciﬁcity. A strong 
correlation was observed between some of these genes. For example, 
high levels of PH4 were related to low or no expression of CA IX (ρ = 
-0.33; p=0.007).
Conclusions: Overexpression of CSF1 and EGFR, and downregulation 
of CA IX was associated with particularly poor prognosis in SqCLC. 
Simultaneous assessment of the expression of these genes deﬁnes the 
group of SqCLC pts who might derive the highest beneﬁt from adju-
vant chemotherapy. 
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Background: Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) are effective vs non-small cell lung cancer 
(NSCLC). Several known factors inﬂuence therapy efﬁcacy. 
Hypothesis: We hypothesized: 1) patient survival curves follow ﬁrst 
order kinetics. 2) Dichotomous (present vs absent) prognostic fac-
tors give inﬂection points on plots of log % cell survival vs time. 3) 
Nonlinear regression analysis of log-linear survival plots might permit 
identiﬁcation and characterization of prognostically distinct subgroups, 
and this could: a) aid in identiﬁcation of prognostic factors b) facilitate 
assessment of whether a therapy was having an impact on a distinct 
subpopulation or on the whole group.
Methods: Since much is already known about impact of EGFR TKIs 
in distinct NSCLC subgroups, we used published survival curves for 
EGFR TKI-treated patients to conduct preliminary assessments of this 
proposed methodology. We manually measured curve height from 215 
published survival or progression-free survival curves, replotted data 
as semilog plots, and performed compartmental nonlinear regression 
analyses using WinNonlin version 5.0.1 to assess number, size and 
half-life of identiﬁable distinct subgroups.
Results: Patterns identiﬁed were 1, 2, and 3 compartment curves, with 
2 compartment curves being most common. Some 1 compartment 
curves were convex, and some of these had a terminal plateau after the 
convexity, suggesting that they actually had a second compartment that 
had not been recognized by the analytical program due to the convex-
ity. Of 199 curves assessed in detail, 16 were 1 compartment without 
convexity, 11 were 1 compartment with convexity, 98 were 2 compart-
ment without convexity, 69 were 2 compartment with convexity in the 
ﬁrst portion, and 5 were 3 compartment. Analyses continue to assess 
whether we can identify speciﬁc treatment parameters or population 
factors that correlate with curve characteristics. 
Conclusions: When log % survival is plotted vs time, most survival 
curves have one or more inﬂection points suggesting distinct subpopu-
lations that differ by one or more dichotomous prognostic factors. 
These early analyses suggest that it is feasible to use compartmental 
nonlinear regression analysis to assess survival curves, although more 
complex modeling will be needed to optimally characterize curves 
with convex early portions. We plan to now use this methodology 
prospectively to link tumor and patient characteristics to prognostic 
subgroups. We will test the hypotheses that: 1) dichotomous variables 
account for curve inﬂection points. 2) The further to the right along 
the survival curve, the more homogeneous the remaining population 
for a phenotype conferring good prognosis. 3) Curve convexities are 
due to speciﬁc treatment practices (eg, discontinuing therapy after a set 
time period) or else are due to identiﬁable epigenetic events triggered 
early in therapy that lead to a maximum attainable survival time. 4) 
Assessment of therapies with respect to changes they induce in relative 
subgroup sizes and half-lives will help elucidate whether a treatment is 
affecting one patient subpopulation to a greater extent than another, and 
whether it is shifting patients from a poor prognosis group to a good 
prognosis group. Support: NCI Cancer Center Support Grant 5-P30 
CA16672 to UTMDACC. 
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Background: Pathologic stage of disease is the most important prog-
nostic factor in non-small cell lung cancer (NSCLC) patients treated 
by surgery. Nevertheless there is a great discrepancy in survival time 
observed within the groups with the same pathologic stage of disease.
The aim of the present study was to assess the prognostic role of pre-
treatment serum level of cytokeratin marker - Cyfra 21-1 and an acute 
phase protein - CRP in NSCLC patients (pts) treated by surgery. 
Methods: 39 pts, 30 men, 9 women, median age 62 (42-78) years, 
treated by surgery entered this study. Pathologic stage of disease was: 
Ia-IIb in 32 pts, IIIa in 4 pts, IIIb in 2 pts and IV in 1 pt ( single homo-
lateral lung metastasis ). Sera for Cyfra 21-1 (Elecsys Roche) and CRP 
(Roche/Hitachi) were obtained before surgery. 
Results: After 2 years of follow up 30 pts were still alive (pathologic 
stage Ia-IIb in 27, IIIa - in 2, and IIIb in 1 ). 9 pts were dead (pathologic 
stage Ia-IIb in 5, IIIa in 2, IIIb in 1 and IV in 1). Pretreatment serum 
CRP exceeded 10 mg/l in 7/9 pts who died and 14/30 pts who were 
